[{"orgOrder":0,"company":"Contract Sales Organization","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Triethanolamine Salicylate","moa":"COX-2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Contract Sales Organization","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Contract Sales Organization \/ Tetra BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Contract Sales Organization \/ Tetra BioPharma"}]

Find Clinical Drug Pipeline Developments & Deals for Triethanolamine Salicylate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Contract Sales Organization

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          Contract Sales Organization

                          Country arrow
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Tetra is finalizing a commercial supply agreement and initiating activities to secure private reimbursement for the two TERPACAN™ products.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 20, 2020

                          Lead Product(s) : Triethanolamine Salicylate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Tetra BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank